Cas9 Stable Cell Line - KG-1a

The KG-1a cell line, derived from a 59-year-old male patient with acute myeloid leukemia (AML), is a mature human model of myeloid leukemia. These suspension cells exhibit an immature, primitive cell-like morphology and express myeloid surface markers such as CD33 and CD13, making them valuable in hematologic malignancy research. The Cas9 Stable Cell Line - KG-1a was constructed by integrating the CRISPR-Cas9 system into KG-1a cells. This modification ensures constitutive expression of the Cas9 nuclease, enabling precise and efficient genome editing without repeated transfections. This cell line maintains stable Cas9 expression during passage culture. It retains characteristics of the parental KG-1a cells, including growth kinetics and surface marker profiles, ensuring experimental consistency.

The Cas9 Stable Cell Line - KG-1a significantly advances leukemia and immunology research. Researchers use it for high-throughput CRISPR screening to identify genes crucial for acute myeloid leukemia (AML) cell survival, drug resistance, or differentiation pathways. By introducing sgRNAs targeting oncogenes such as FLT3 or RUNX1, scientists can mimic driver mutations to study leukemia development mechanisms or test targeted therapies. The Cas9-KG-1a cell line also facilitates gene knock-in studies, such as inserting fluorescent tags or point mutations to track protein dynamics or mimic patient-specific variations. In drug development, it can rapidly validate therapeutic targets by generating homologous knockout clones for phenotypic comparisons (e.g., apoptosis or proliferation analysis).